Latest News

Bicycle Therapeutics: Announces First Patient Dosed in Phase I Dose Escalation of BT5528 in Combination with Nivolumab

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that the first patient has been dosed in a Phase I dose escalation of BT5528 in combination with nivolumab. The Phase I trial includes both a monotherapy arm as well as a combination arm.

05 May 2020
Read more

Guest Article by our MD Carolyn Ng for the Timmerman Report: “Singapore’s COVID19 Crisis: Forgetting to Check the Blind Spot”

Despite being a densely populated high-risk state, Singapore managed to keep its cases extremely low. No deaths were reported between late January and mid-March. But even then, there were warning signs. In that same piece, I expressed concern for a potential second wave of cases that could be triggered by the massive influx of Malaysian foreign workers who rushed to enter Singapore before Malaysia closed its borders on Mar. 18. Interestingly, while Singapore did experience a second wave in late March, the new cases were not attributed to foreign workers. Most of the new cases were from Singaporeans returning home from travels to global hotspots such as the UK and US

22 Apr 2020
Read more

Vertex Ventures HC’s Jeff Schlosser’s invention won this year’s Gold Edison Award.

Walter is honored! The WalterLorenz® Surgical Assist Arm was recently awarded a Gold Edison Award™ in their Medical/Dental category for Advanced Surgical Instruments.

06 Apr 2020
Read more

Guest Article by our MD Carolyn Ng for the Timmerman Report: “Singapore: Braving the Second Wave of COVID19”

A day after my article was published, it was announced that two patients (a 75-year-old female, and a 64-year-old male) died in Singapore from COVID19-related complications. Not unexpectedly, the country is now facing a second and larger wave of case spikes. The main reason for the surge in cases is coming from Singaporeans and long-term residents returning home from the UK and US, where uncontained outbreaks have clearly been raging for weeks, largely undetected. At this point in writing, Singapore has reported a total of 732 confirmed cases in the country – more than double from 313 a week ago.

27 Mar 2020
Read more

Guest Article by our MD Carolyn Ng for the Timmerman Report: “Singapore: What We Can Learn From a High-risk Country’s Response to COVID19”

Since the first confirmed case was identified in Singapore 55 days ago, the country has done a remarkable job of containment and mitigation. As of this writing, there have only been 313 confirmed COVID19 cases in Singapore with no COVID-related deaths. Those are remarkably low numbers compared with South Korea, Italy, Iran and other countries.

19 Mar 2020
Read more

Obsidian: Announces Advisory Board

CAMBRIDGE, Mass., Feb. 5, 2020 – Obsidian Therapeutics, a biotechnology company pioneering controllable cell and gene therapies, announced the formation of its Scientific Advisory Board (SAB). Obsidian’s SAB is comprised of distinguished research scientists, professors and industry experts recognized as key opinion leaders in the fields of immuno-oncology, synthetic biology, and cell and gene therapy.

05 Feb 2020
Read more

Get In Touch

    Our Global Network

    Vertex Ventures HC is part of the global Vertex Ventures network of funds.


    In addition to the HC Fund, the Vertex Global Network is comprised of affiliates in Israel, China, Southeast Asia and India. Leveraging the combined experience and resources of our extensive partner network enables our portfolio companies to realize their full potential.

    Copyright

    © 2019 by Vertex Ventures

    All rights reserved.

    Legal